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In the winter of 2014/15 a novel GII.P17-GII.17 norovi-
rus strain (GII.17 Kawasaki 2014) emerged, as a major 
cause of gastroenteritis outbreaks in China and Japan. 
Since their emergence these novel GII.P17-GII.17 
viruses have replaced the previously dominant GII.4 
genotype Sydney 2012 variant in some areas in Asia 
but were only detected in a limited number of cases on 
other continents. This perspective provides an over-
view of the available information on GII.17 viruses in 
order to gain insight in the viral and host character-
istics of this norovirus genotype. We further discuss 
the emergence of this novel GII.P17-GII.17 norovirus 
in context of current knowledge on the epidemiology 
of noroviruses. It remains to be seen if the currently 
dominant norovirus strain GII.4 Sydney 2012 will be 
replaced in other parts of the world. Nevertheless, 
the public health community and surveillance systems 
need to be prepared in case of a potential increase of 
norovirus activity in the next seasons caused by this 
novel GII.P17-GII.17 norovirus.
In this issue of  Eurosurveillance, observations from 
Japan are reported on an unusual prevalence of a pre-
viously rare norovirus genotype, GII.17, in diarrheal 
disease outbreaks at the end of the 2014/15 winter 
season [1], similar to what was observed for China 
[2,3]. Norovirus is a leading cause of gastroenteritis [4]. 
Although the infection is self-limiting in healthy indi-
viduals, clinical symptoms are much more severe and 
can last longer in immunocompromised individuals, 
the elderly and young children [5,6]. 
The Norovirus genus comprises seven genogroups (G), 
which can be subdivided in more than 30 genotypes 
[7]. Viruses belonging to the GI, GII and GIV geno-
groups can infect humans, but since the mid-1990s 
GII.4 viruses have caused the majority (ca 70–80%) 
of all norovirus-associated gastroenteritis outbreaks 
worldwide [8-10]. 
GII.4 viruses can continue to cause widespread disease 
in the human population because they evolve through 
accumulations of mutations into so-called drift vari-
ants that escape immunity from previous exposures 
[11]. Contemporary GII.4 noroviruses also demonstrate 
intra-genotype recombination near the junction of 
open reading frame (ORF) 1 and ORF2, which is likely 
to foster the emergence of novel GII.4 variants [12]. In 
addition, the binding properties of GII.4 viruses have 
altered over time, resulting in a larger susceptible host 
population [13].
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Emergence and geographical spread of 
GII.17 genotype noroviruses
Viruses of the GII.17 genotype have been circulating 
in the human population for at least 37 years; the first 
GII.17 strain in the National Center for Biotechnology 
Information (NCBI) databank is from 1978 [14]. Since 
then viruses with a GII.17 capsid genotype have spo-
radically been detected in Africa, Asia, Europe, North 
America and South America (Table, Figure 1). The virus 
appears to be clinically relevant, as it has been asso-
ciated with acute gastroenteritis (AGE) in children and 
adults, and with chronic infection in an immunocom-
promised renal transplant patient [15] and a leukaemia 
patient (unpublished data). In the United States (US), 
only four GII.17 outbreaks were reported between 2009 
to 2013 through CaliciNet, with a median of 11.5 people 
affected by each outbreak [16]. In Noronet, an informal 
international network of scientists working in public 
health institutes or universities sharing virological, epi-
demiological and molecular data on norovirus, GII.17 
cases were also sporadically reported in Denmark and 
South Africa during this period [17].
More widespread circulation of GII.17 was first reported 
for environmental samples in Korea from 2004 to 2006. 
This information was published in a report in 2010 by 
the Korean Food and Drug Administration (KFDA) and 
was cited by Lee et al. [18], but the original docu-
ment describing this finding is not publicly available 
and there are no matching clinical reports. From 2012 
to 2013 a novel GII.17 virus accounted for 76% of all 
detected norovirus strains in rivers in rural and urban 
areas in Kenya [19]. In the winter of 2014/15, geneti-
cally closely related GII.17 viruses were first detected 
in AGE outbreaks in the Guangdong province in China 
in schools, colleges, factories and kindergartens [3]. 
Sequence analyses demonstrated that 24 of the 29 
reported outbreaks during that winter were caused 
by GII.17. A large increase in the incidence of AGE out-
breaks was also reported; 29 outbreaks associated 
with 2,340 cases compared with nine outbreaks and 
949 cases in the previous winter when GII.4 Sydney 
2012 still was the dominant genotype [3].
During the same winter there was also an increase in 
outbreak activity in Jiangsu province, which could be 
attributed to the emergence of this novel GII.17 [2]. 
This triggered us to investigate the prevalence of GII.17 
in other parts of the world by means of a literature 
study and by inviting researchers collaborating within 
Noronet to share their data on GII.17. Currently, in Asia, 
in addition to Guangdong and Jiangsu [2,3], the novel 
GII.17 is also the predominant genotype in Hong Kong 
(unpublished data) and Taiwan [20], while in Japan, a 
sharp increase in the number of cases caused by this 
novel virus has been observed during the 2014/15 
winter season [1]. Related viruses have been detected 
sporadically in the US [21] (http://www.cdc.gov/norovi-
rus/reporting/calicinet/index.html), Australia, France, 
Italy, Netherlands, New-Zealand and Russia (unpub-
lished data,  www.noronet.nl) (Figure 1). In France the 
novel GII.17 virus appeared at the beginning of 2013, 
Figure 1
World map showing areas where GII.17 norovirus strains have been detected, 1978–2015
Sporadic detection of the novel GII.17 virus
The novel GII.17 is the predominant genotype Major outbreaks of the novel GII.17 virus
Sporadic detection of GII.17 viruses from before the emergence of the novel GII.17 virus



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































but since then, it has not resulted in an increase in AGE 
outbreaks as observed in China, nor replaced the pre-
dominant GII.4 in the last seasons (data not shown). 
Based on sequence analyses of the ORF1-ORF2 junction 
region, most diagnostic real-time transcription poly-
merase chain reactions (PCRs) will be able to detect 
this novel GII.17 virus, but it is not known whether the 
same holds true for immunoassays. However, only a 
small portion of norovirus outbreaks are typed beyond 
the GI and GII classification, therefore it is possible 
that GII.17 is more prevalent than we currently suspect.
Phylogenetic analyses and molecular 
characterisation of the novel GII.17 viruses
Phylogenetic analysis of the viral protein 1 (VP1) of 
GII.17 strains in the NCBI database demonstrated at 
least two clusters, with the novel Asian GII.17 strains 
grouping together with the GII.17 strains detected in 
the surface water in Kenya (Figure 2,[21]) and in an 
outbreak in 2012 in Korea [22]. Although the novel 
GII.17 clusters away from previously identified GII.17 
strains, the amino acids changes in VP1 are not suf-
ficient to separate it into a different genotype. For 
only a limited number of GII.17 strains the full VP1 has 
been sequenced, which demonstrated three deletions 
and at least one insertion compared with previous 
GII.17 strains (comprehensive alignments are given in 
Fu et al. and Parra et al. [2,21]). The majority of these 
changes could be mapped in or near major epitopes of 
the VP1 protein and potentially result in antigenic drift 
or altered receptor-binding properties [21]. Most pub-
licly available GII.17 sequences only comprise the VP1, 
and most frequently the 5’-end of VP1 (C region), while 
most of the observed diversity within the GII.17 geno-
type is observed in the 3’-end of VP1 (D region) [23].
Previously, viruses with a GII.17 VP1 genotype con-
tained a GII.P13 ORF1 genotype, although recombinants 
with an ORF1 GII.P16, GII.P3 and GII.P4 genotype have 
also been identified (Table). Sequence comparison 
showed that the ORF1 region of the novel GII.17 viruses 
was not detected before and cluster between GII.P3 
and GII.P13 viruses [21]. Since this is the first orphan 
ORF1 sequence associated with GII.17, it has been des-
ignated GII.P17 according to the criteria of the proposal 
for a unified norovirus nomenclature and genotyp-
ing [24]. The novel GII.17 virus was termed Kawasaki 
2014 after the first near complete genome sequence 
(AB983218) submitted to GenBank. Noronet provides 
a publicly available and widely used tool for the typ-
ing of norovirus sequences (http://www.rivm.nl/mpf/
norovirus/typingtool). This typing tool was updated 
to ensure correct classification of both ORF1 and ORF2 
sequences of the newly emerged GII.P17-GII.17 viruses.
The acquisition of a novel ORF1 could potentially result 
in an increase in replication efficiency and may – in 
part – explain the increase of the AGE outbreak activity. 
Histo-blood group antigens (HBGAs) function as (co-)
























































































































































































































































































































































































































































































2 (FUT2) adds an alpha-1,2 linked fucose on HBGAs, 
and individuals lacking the FUT2 gene are referred to 
as ‘non-secretors’, while those with a functional FUT2 
gene are called ‘secretors’. Non-secretors have been 
shown to be less susceptible to infection with sev-
eral norovirus genotypes [25]. In studies investigat-
ing the genetic susceptibility to norovirus genotypes, 
a secretor patient with blood type O Lewis phenotype 
Lea-b +  and a secretor patient with blood type B Lewis 
phenotype Lea-b- were positive for previously identified 
GII.17 viruses and no non-secretors were found 
positive [26,27], suggesting that there could be genetic 
restrictions for GII.17 viruses in infection of humans. 
How the observed genetic changes have affected the 
antigenic and binding properties of the novel GII.17 
strains, and hereby the susceptible host population, 
remains to be discovered.
Public health implications
Based on the emergence and spread of new GII.4 vari-
ants, we know that noroviruses are able to rapidly 
spread around the globe [28,29]. The novel GII.17 virus 
has been detected in sporadic cases throughout the 
world, but until now it has not resulted in an increase 
Figure 2
Unrooted maximum likelihood phylogenetic tree based on the 5’-end of virus protein 1 (VP1) sequences (C region) of GII.17 
noroviruses, available from the National Center for Biotechnology Information (NCBI)
The tree was estimated under the general time reversible model using PhyML. Bootstrap values above 70% are given. Sequences from 
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in outbreak activity or replacement of GII.4 Sydney 
2012 viruses outside of Asia. Following the patterns 
observed in the past years for GII.4 noroviruses and 
based on the data from China and Japan, an increase 
in norovirus outbreak activity can be expected if the 
currently dominant GII.4 is replaced by GII.17. Another 
possibility – however – would be some restriction to 
global expansion, as has been observed previously 
for the norovirus variant GII.4 Asia 2003 [29]. Such 
restrictions could be due to differences in pre-existing 
immunity, but could also be the result of differences 
between populations in the expression of norovirus 
receptors [29]. Based on current literature on the novel 
GII.17 virus there is no indication that it will be more 
virulent compared with GII.4. Nevertheless, the public 
health community and surveillance systems need to be 
prepared in case of a potential increase of norovirus 
activity by this novel GII.17 virus.
Conclusions
Understanding the epidemiology of norovirus geno-
types is important given the development of vaccines 
that are entering clinical trials. Current candidate vac-
cines have targeted the most common norovirus geno-
types, and it remains to be seen if vaccine immunity 
is cross-reactive with GII.17 viruses [30]. Contemporary 
norovirus diagnostic assays may not have been devel-
oped to detect genotype GII.17 viruses since this geno-
type was previously only rarely found during routine 
surveillance. These assays need to be evaluated and 
updated if necessary to correctly diagnose norovi-
rus outbreaks caused by the emerging GII.17 virus. 
Norovirus strain typing ideally should include ORF1 
sequences and the variable VP1 ‘D’ region as well as 
metadata on the host, like clinical symptoms, immune 
status and blood group. This will allow us to better 
study and monitor the genetic disposition, pathogene-
sis, evolution and epidemiology of this newly emerged 
virus.
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